Trading Update

16 October 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced a trading update, pre-audit, for its financial year ended 30 September 2025 ("FY25").

• FY25 revenues exceed market expectations at £6.5 million (2024: £5.8 million). Year-on-year revenues increased by 13% reflecting new contract wins, existing contract extensions and a broadening of market offering into new verticals.
• Year-end order book of £13.8 million (2024: £15.3 million). In H2, the order book increased from £13.1 million (31 March 2025) reflecting £4.2 million of new contract wins and contract extensions offset by £3.3 million of revenues recognised and £0.2 million of minor project scope and foreign exchange adjustments.
• Acceleration of new wins is continuing into FY26 with £0.9 million of new contracts and contract extensions signed since the end of September.
• Year-end cash of £3.5 million (2024: £1.8 million). Year-on-year increase reflects a £3.7 million (net of fees) capital raise completed in H1-25 offset by investments made in the Company's I-L-S strategy.
• Full year loss before interest, tax, depreciation, and amortisation ("EBITDA") is expected to be slightly improved on market expectations at no more than a £1.6 million loss (2024: £1.7 million loss). This reflects the double-digit revenue growth offset by specific investments designed to sustain this rate of growth in future years.

The Company intends to announce its audited results for FY25 in December 2025.

Bram Goorden, CEO of IXICO, commented: "I am thrilled with the performance of the IXICO team this first full financial year of my tenure with the Company. The oversubscribed capital raise at the start of the year allowed us to double down investments in specific areas of growth targeting new customers and novel verticals. It is my strong belief that these initial positive signals will translate into a sustained period of growth and value creation as we further scale our impact in the thriving market of neurodegenerative disease biopharma R&D. Failure is not an option. Patients are waiting for solutions, and the biopharma industry is working harder than ever in CNS to develop treatments."